8-K: Zomedica Continues Dialogue with NYSE American Regarding Listing Compliance

Zomedica is in ongoing discussions with the NYSE American to address non-compliance with listing standards after a proposed reverse stock split was rejected by shareholders.

Summary

• Zomedica is working with the NYSE American to regain compliance with listing standards.
• The company received a notice of non-compliance on September 13, 2023, due to its share price trading below $0.20 for a sustained period.
• Zomedica had until March 12, 2024, to implement a reverse stock split or show sustained price improvement.
• A proposed 80:1 reverse stock split was rejected by shareholders at a special meeting on February 28, 2024.
• The NYSE American will continue to monitor Zomedica's share price, and further price deterioration could lead to delisting.
• Zomedica's shares will remain listed on the NYSE American for now.

Sentiment

Score: 3

Explanation: The document highlights significant challenges for Zomedica, including non-compliance with listing standards and the rejection of a key measure to address it. The risk of delisting is a major concern, leading to a negative sentiment.

Positives

• Zomedica is actively engaging with the NYSE American to address the listing compliance issue.
• The company's shares remain listed on the NYSE American at this time.
• Zomedica has time to demonstrate the progress it has made and highlight future opportunities to improve its share price.

Negatives

• Zomedica is not in compliance with NYSE American listing standards.
• The company's share price has been trading at a low level.
• A proposed reverse stock split was rejected by shareholders.
• There is a risk of delisting if the share price continues to decline.

Risks

• The company faces the risk of being delisted from the NYSE American if its share price does not improve.
• The rejection of the reverse stock split by shareholders complicates the company's efforts to regain compliance.
• Continued low share price could negatively impact investor confidence and the company's ability to raise capital.
• The company's future performance is subject to various risks and uncertainties, including market conditions and competition.

Future Outlook

The company will continue to engage with the NYSE American and work to improve its share price, but there is no guarantee of success and the risk of delisting remains.

Management Comments

• Larry Heaton, Chief Executive Officer of Zomedica Corp. stated, 'Following the rejection of our proposed reverse stock split, we have been in contact with the NYSE American to understand the implications for Zomedica's continued listing.'
• The exchange has indicated that they will continue to monitor our share price and other developments and noted that additional deterioration of the share price could result in delisting.
• This gives us time to continue to highlight the progress the Company has made over the last several years, and the tremendous opportunities ahead, to positively impact our share price.

Industry Context

The veterinary health industry is competitive, and Zomedica's challenges with its share price highlight the importance of financial stability and investor confidence in this sector.

Comparison to Industry Standards

• Many companies in the veterinary health sector, such as IDEXX Laboratories and Zoetis, maintain higher share prices and are not facing similar delisting risks.
• Zomedica's situation is unusual compared to established players in the industry, who typically have strong financial performance and investor support.
• The rejection of the reverse stock split suggests a lack of shareholder confidence in the company's current strategy.

Stakeholder Impact

• Shareholders face the risk of further share price decline and potential delisting.
• Employees may be concerned about the company's future stability.
• Customers and suppliers may have concerns about the company's long-term viability.

Next Steps

• Zomedica will continue discussions with the NYSE American regarding its listing status.
• The company will work to improve its share price and demonstrate its progress to the exchange.
• Zomedica will continue to highlight the progress the Company has made over the last several years, and the tremendous opportunities ahead, to positively impact our share price.

Key Dates

Keywords

NYSE American, listing compliance, reverse stock split, share price, delisting, veterinary health, Zomedica, ZOM